To develop the first drugs that combat cancer heterogeneity, the key reason for poor survival outcomes of cancer patients,

We develop drugs for complete and durable responses to limit relapse, metastasis and save lives. 

Every cancer undergoes an evolutionary process which generates billions of mutationally and biologically diverse cells. This is why genetically targeted therapeutics only work for less than half of the patients they are designed to treat and responses endure only for a few months.

Enedra harnesses the power of Synthetic Lethality and Advanced Computational Systems Biology and discovers the first therapeutics that work against the complexity, biological and mutational heterogeneity of cancer.